In this narrative review article, we discuss the putative role of GLP-1 RAs in the treatment of patients with hepatocellular carcinoma, and especially NASH-related HCC, focusing on the molecular pathways that could justify a possible benefit. This evidence concerns the gene GCG and hepatocellular carcinoma.